Alba Fiorentino1, Fabiana Gregucci2, Ilaria Bonaparte1, Nicola Vitulano3, Alessia Surgo1, Rosario Mazzola4, Antonio Di Monaco3, Roberta Carbonara1, Filippo Alongi4, Tommaso Langialonga3, Massimo Grimaldi3. 1. Department of Radiation Oncology, General Regional Hospital "F. Miulli", Strada Prov 127, 70021, Acquaviva delle Fonti, Bari, Italy. 2. Department of Radiation Oncology, General Regional Hospital "F. Miulli", Strada Prov 127, 70021, Acquaviva delle Fonti, Bari, Italy. fabianagregucci@gmail.com. 3. Department of Cardiology, General Regional Hospital "F. Miulli", Acquaviva delle Fonti, Bari, Italy. 4. Department of Radiation Oncology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar-Verona, Italy.
Abstract
AIM: Stereotactic ablative radiation therapy (SABR) is used in non-oncologic indications, recently even for cardiac arrhythmias. Thus, aim of this analysis is to review preclinical, early clinical evidences and future direction of the latter new treatment approach. METHOD: A collection of available data regarding SABR and cardiac arrhythmias was made, by Pubmed research and 2 independent researchers, including preclinical and clinical data. A review of ongoing trials was conducted on ClinicalTrials.gov. RESULTS: Preclinical research conducted in animal models showed that a safe and effective noninvasive treatment approach for cardiac arrhythmias could be represented by SABR with a median time of response around 2-3 months. The treatment dose plays a crucial role: the atrioventricular node would seem more radiosensitive than the other cardiac electric zones. Clinical data, such as published case series, case reports and early prospective studies, have already suggested the feasibility, efficacy and safety of SABR (25 Gy in one session) for refractory ventricular arrhythmias. CONCLUSION: Considering the ongoing trials of SABR and new technological improvements in radiotherapy (e.g. hybrid magnetic resonance) and in arrhythmias noninvasive mapping systems, the future analyses will improve the reliability of those preliminary results.
AIM: Stereotactic ablative radiation therapy (SABR) is used in non-oncologic indications, recently even for cardiac arrhythmias. Thus, aim of this analysis is to review preclinical, early clinical evidences and future direction of the latter new treatment approach. METHOD: A collection of available data regarding SABR and cardiac arrhythmias was made, by Pubmed research and 2 independent researchers, including preclinical and clinical data. A review of ongoing trials was conducted on ClinicalTrials.gov. RESULTS: Preclinical research conducted in animal models showed that a safe and effective noninvasive treatment approach for cardiac arrhythmias could be represented by SABR with a median time of response around 2-3 months. The treatment dose plays a crucial role: the atrioventricular node would seem more radiosensitive than the other cardiac electric zones. Clinical data, such as published case series, case reports and early prospective studies, have already suggested the feasibility, efficacy and safety of SABR (25 Gy in one session) for refractory ventricular arrhythmias. CONCLUSION: Considering the ongoing trials of SABR and new technological improvements in radiotherapy (e.g. hybrid magnetic resonance) and in arrhythmias noninvasive mapping systems, the future analyses will improve the reliability of those preliminary results.
Authors: Alba Fiorentino; Antonio Di Monaco; Alessia Surgo; Nicola Vitulano; Fabiana Gregucci; Elena Ludovico; Roberta Carbonara; Federico Quadrini; Giuseppe Rubini; Ilaria Bonaparte; Massimo Grimaldi Journal: Clin Case Rep Date: 2020-11-21
Authors: Antonio Di Monaco; Fabiana Gregucci; Ilaria Bonaparte; Federica Troisi; Alessia Surgo; Domenico Di Molfetta; Nicola Vitulano; Federico Quadrini; Roberta Carbonara; Gaetano Martinelli; Pietro Guida; Maria Paola Ciliberti; Alba Fiorentino; Massimo Grimaldi Journal: Front Cardiovasc Med Date: 2022-03-02
Authors: Marcin Miszczyk; Mateusz Sajdok; Jerzy Nożyński; Magdalena Cybulska; Jacek Bednarek; Tomasz Jadczyk; Tomasz Latusek; Radoslaw Kurzelowski; Łukasz Dolla; Wojciech Wojakowski; Agnieszka Dyla; Michał Zembala; Anna Drzewiecka; Konrad Kaminiów; Anna Kozub; Ewa Chmielik; Aleksandra Grza Dziel; Adam Bekman; Krzysztof Stanisław Gołba; Sławomir Blamek Journal: Front Cardiovasc Med Date: 2022-07-07